Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an ...

We don't need to dwell on the lack of detail behind Andrew Witty stepping down as CEO of UnitedHealth ( UNH) for "personal ...

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Halozyme Therapeutics (HALO) stock remains under pressure as Morgan Stanley downgrades the company on Medicare price negotiation concerns. Read more here.

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...